{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:04:39Z","timestamp":1776391479274,"version":"3.51.2"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T00:00:00Z","timestamp":1636243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real\u2010world and long\u2010term data on biologic treatment changes \u2013 including switching, discontinuation, dose escalation, and interval change (both increasing and decreasing) \u2013 are required to understand treatment patterns for psoriasis (PsO) in Canada. The study objectives were to evaluate the time to first biologic treatment change and to document these changes in Canadian patients with moderate\u2010to\u2010severe chronic plaque PsO. Charts from 13 Canadian sites were queried retrospectively (2005\u20132019); a period covering all biologic classes commonly used for PsO in Canada. Included were patients diagnosed with, and currently using biologics for, moderate\u2010to\u2010severe chronic plaque PsO. Time to first treatment change, nature of treatment change, number of lines of treatment, proportion of patients on each drug, and drug survival were collected. Based on 1149 medical charts, adalimumab had the longest time to first treatment change (49.3\u00a0months; 95% confidence interval, 37.4\u201367.4). Approximately half of the patients had a treatment change, and nearly 75% of these changes were either an interval change or a biologic switch. Lack of efficacy was the most prevalent primary reason for biologic switch (67.3%), whereas 6.7% of patients switched due to adverse events. Drug survival for etanercept and infliximab was approximately twice as long for patients who had dose optimization (i.e., dose escalation or interval change) than patients without dose optimization. The survival curve of adalimumab was similar to the one of ustekinumab after 48\u00a0months of treatment, showing approximately 60% of patients remaining on treatment after 132\u00a0months, with or without dose optimization. Assessing treatment patterns of all commonly used biologics for moderate\u2010to\u2010severe chronic plaque PsO in Canada between 2005 and 2019 showed that approximately half of the patients required a treatment change (mainly interval change or biologic switch) while the other half remained on treatment.<\/jats:p>","DOI":"10.1111\/1346-8138.16214","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T07:23:30Z","timestamp":1636356210000},"page":"95-105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real\u2010world, long\u2010term treatment patterns of commonly used biologics in Canadian patients with moderate\u2010to\u2010severe chronic plaque psoriasis"],"prefix":"10.1111","volume":"49","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"SkiN Centre for Dermatology  Peterborough Ontario Canada"},{"name":"Queen\u2019s University  Kingston Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Lynderm Research Inc.  Markham Ontario Canada"},{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Brunswick Dermatology Center  Fredericton New Brunswick Canada"},{"name":"Department of Medicine Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Avadisian","sequence":"additional","affiliation":[{"name":"AbbVie Corporation  Saint\u2010Laurent QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Labelle","sequence":"additional","affiliation":[{"name":"AbbVie Corporation  Saint\u2010Laurent QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"K. Papp Clinical Research  Waterloo Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1767590"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420932514"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13860"},{"key":"e_1_2_7_12_1","first-page":"569","article-title":"Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting","volume":"106","author":"Baniandr\u00e9s O","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.3.201"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15027"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14834"},{"key":"e_1_2_7_18_1","first-page":"1","article-title":"Switching biologics in the treatment of psoriasis: a multicenter experience","volume":"19","author":"\u00d6zkur E","year":"2019","journal-title":"Dermatology"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0603-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14145"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417733957"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18981"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17738"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14782"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15146"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12654"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13611"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.037"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1480746"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34293-y"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1398393"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00969-8"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-018-0074-0"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12548"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329504"},{"key":"e_1_2_7_38_1","unstructured":"ClinicalTrials.gov.Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03982394. 2021 Accessed September 14 2021."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.023"},{"key":"e_1_2_7_41_1","unstructured":"AbbVie Corporation.Humira Product Monograph.2019."},{"key":"e_1_2_7_42_1","article-title":"Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival","author":"Llamas\u2010Velasco M","year":"2020","journal-title":"Dermatol Ther"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466978"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:00:46Z","timestamp":1722582046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/1346-8138.16214"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16214","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,7]]},"assertion":[{"value":"2021-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}